Agilon Health | AGL | Long at $2.36Reentering this trade (original: )
Agilon Health NYSE:AGL
Pros:
Revenue consistently grew from 2019 ($794 million) to 2024 ($6.06 billion). Expected to reach $9.16 billion by 2028.
Current debt-to-equity ratio 0.07 (very low)
Sufficient cash reserves to fund operations and strategic initiatives
Strong membership growth (659,000 in 2024, a 38% year-over-year increase)
Recent insider buying ($2 - $3) and awarding of options
Cons:
Rising medical costs - currently unprofitable and not forecast to become profitable over the next 3 years
Medicare Advantage Membership issues with the new political administration
No dividend
It's a gamble and I think it's a possibility this could drop near $1 in the near-term due to the Medicaid changes/fear... regardless, long-term, personal buy-zone at $2.36.
Targets in 2027
$3.70 (+56.8%)
$5.25 (+122.5%)
